Amid concerns over Covid vaccine supplies dragging down India's vaccination drive, the government has said that the supply of Bharat Biotech's Covaxin fell short of target owing to quality concerns over the first few batches of the vaccine.
Also See | Big trouble for Bharat Biotech, US partner faces accusation of fraud on Covaxin statements
In an interview to NDTV, Covid task force member Dr NK Arora, who is also the head of the govt vaccine panel, said that the first few batches of Covaxin produced at the company's facility in Bengaluru were not of the right quality.
"These batches, which were not of the right quality, were never released for the national vaccination campaign," Dr Arora added in the interview.
Dr Arora admitted that the government was banking on a much sharper rise in the production of Covaxin - one of the two main vaccines in use in India - but was set back because of the quality issues.
Also See | Results of Covaxin trials on children likely by September, AIIMS Director said